Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients

详细信息    查看全文

• 作者：Gaeun Kang ; Ka-Rham Kim ; Hyun-Jeong Shim ; Jun-Eul Hwang ; Woo-Kyun Bae ; Ik-Joo Chung ; Hee-Nam Kim ; Jongtae Lee ; Kyungmee Choi ; Hee-Young Shin ; Jong-Keun Kim ; Seong-Wook Jeong and Sang-Hee Cho
• 刊名：Asia-Pacific Journal of Clinical Oncology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：13
• 期：1
• 页码：53-60
• 全文大小：233K
• ISSN：1743-7563

文摘

Despite appropriate use of antiemetics including 5-hydroxytryptamine type 3 (5-HT₃) receptor antagonists, chemotherapy-induced nausea and vomiting (CINV) is still an unsolved problem in patients with anticancer drugs. We examined whether the variants of ABCB1, CYP2D6 and HTR3B affect efficacy of ramosetron, a selective 5-HT₃ receptor antagonist in a dose escalation clinical trial.